Objective:
The diagnosis of partial androgen insensitivity syndrome (PAIS) should be reserved for infants with a pathogenic androgen receptor gene (AR) mutation. However, only about 20% of infants with a clinical phenotype akin to PAIS have an AR mutation. We aimed to identify clinical features associated with the presence of an AR mutation.
Methods:
The external masculinisation score (EMS; normal=12), birth weight (BW), gestational age and BW SD score (BW-SDS) of 164 infants with a 'PAIS-like' phenotype were analysed in the Cambridge Disorders of Sex Development (DSD) Database, of whom 128 (78%) had no AR mutation ('AR mutation-negative') and 36 (22%) had an AR mutation ('AR mutation-positive').
Results:
The EMS was similar in AR mutation-negative and AR mutation-positive infants (median, IQR: 5.0, 3.0 to 6.0 vs 4.8, 3.0 to 6.0; p=0.33). AR mutation-negative infants had lower BW (2.33, 1.38 to 3.20 vs 3.18, 2.87 to 3.61 kg; p<0.001), lower gestational age (37.0, 34.0 to 40.0 vs 40.0, 39.0 to 40.0 weeks; p<0.001), and lower BW-SDS (-1.31, -2.33 to -0.46 vs -0.57, -1.19 to 0.33; p=0.001) compared to AR mutation-positive infants. More AR mutation-negative infants (47/128; 37%) than AR mutation-positive infants (2/36; 6%) had BW-SDS <-2 (p<0.001).
Conclusions:
The severity of genital anomalies in this large cohort of infants with a 'PAIS-like' phenotype did not differentiate their AR status. Almost all the infants born small-for-gestational-age do not have an AR mutation. A category of 'XY DSD and fetal growth restriction, as yet unexplained' should be recognised.
Citing Articles
Molecular genetic diagnosis and surgical management in a cohort of children with 46,XY disorders/differences of sex development.
Wong Y, Luk H, Yau H, Wong L, Poon S, Tung J
Front Pediatr. 2025; 13:1456227.
PMID: 39936125
PMC: 11810906.
DOI: 10.3389/fped.2025.1456227.
El laboratorio en el diagnóstico multidisciplinar del desarrollo sexual anómalo o diferente (DSD): III) Marcadores bioquímicos y genéticos en los 46,XY IV) Propuestas para el diagnóstico diferencial de los DSD.
Granada M, Audi L
Adv Lab Med. 2023; 2(4):494-515.
PMID: 37360897
PMC: 10197789.
DOI: 10.1515/almed-2020-0120.
The laboratory in the multidisciplinary diagnosis of differences or disorders of sex development (DSD): III) Biochemical and genetic markers in the 46,XYIV) Proposals for the differential diagnosis of DSD.
Granada M, Audi L
Adv Lab Med. 2023; 2(4):494-515.
PMID: 37360892
PMC: 10197773.
DOI: 10.1515/almed-2021-0043.
A Single-Center, Observational Study of 607 Children and Young People Presenting With Differences of Sex Development (DSD).
Man E, Mushtaq I, Barnicoat A, Carmichael P, Hughes C, Davies K
J Endocr Soc. 2022; 7(1):bvac165.
PMID: 36419940
PMC: 9676112.
DOI: 10.1210/jendso/bvac165.
[A deep intronic mutation in AR gene causing androgen insensitivity syndrome: difficulties of diagnostics].
Kalinchenko N, Petrov V, Panova A, Tiulpakov A
Probl Endokrinol (Mosk). 2021; 67(5):48-52.
PMID: 34766490
PMC: 9753799.
DOI: 10.14341/probl12799.
Let's Talk about Placental Sex, Baby: Understanding Mechanisms That Drive Female- and Male-Specific Fetal Growth and Developmental Outcomes.
Meakin A, Cuffe J, Darby J, Morrison J, Clifton V
Int J Mol Sci. 2021; 22(12).
PMID: 34203717
PMC: 8232290.
DOI: 10.3390/ijms22126386.
Towards improved genetic diagnosis of human differences of sex development.
Delot E, Vilain E
Nat Rev Genet. 2021; 22(9):588-602.
PMID: 34083777
PMC: 10598994.
DOI: 10.1038/s41576-021-00365-5.
Reference growth data in 46,XY disorders of sex development from a single center.
Saenger P
Pediatr Investig. 2020; 1(1):20.
PMID: 32851212
PMC: 7331342.
DOI: 10.1002/ped4.12012.
Discordant sex between fetal screening and postnatal phenotype requires evaluation.
Byers H, Neufeld-Kaiser W, Chang E, Tsuchiya K, Oehler E, Adam M
J Perinatol. 2018; 39(1):28-33.
PMID: 30459335
PMC: 6340391.
DOI: 10.1038/s41372-018-0278-5.
Predicting puberty in partial androgen insensitivity syndrome: Use of clinical and functional androgen receptor indices.
Lek N, Tadokoro-Cuccaro R, Whitchurch J, Mazumder B, Miles H, Prentice P
EBioMedicine. 2018; 36:401-409.
PMID: 30316867
PMC: 6197786.
DOI: 10.1016/j.ebiom.2018.09.047.
New technologies to uncover the molecular basis of disorders of sex development.
Barseghyan H, Delot E, Vilain E
Mol Cell Endocrinol. 2018; 468:60-69.
PMID: 29655603
PMC: 7249677.
DOI: 10.1016/j.mce.2018.04.003.
Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity.
Hornig N, Ukat M, Schweikert H, Hiort O, Werner R, Drop S
J Clin Endocrinol Metab. 2016; 101(11):4468-4477.
PMID: 27583472
PMC: 5095254.
DOI: 10.1210/jc.2016-1990.
Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015).
Ahmed S, Achermann J, Arlt W, Balen A, Conway G, Edwards Z
Clin Endocrinol (Oxf). 2015; 84(5):771-88.
PMID: 26270788
PMC: 4855619.
DOI: 10.1111/cen.12857.